SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report Of Foreign Issuer Pursuant To Rule 13a-16 Or 15d-16 of the Securities Exchange Act of 1934

For the month of January 2003

ALCON, INC.

Bösch 69 P.O. Box 62 6331 Hünenberg, Switzerland 011-41-41-785-8888 (Address of principal executive offices)

[Indicate by check mark whether the 20-F or Form 40-F.]	registrant fi	les or will file annual reports under cover Form
Form 20-F _	X	Form 40 F
-	information	by furnishing the information contained in this to the Commission pursuant to Rule 12g3-2(b)
Yes _		No <u>x</u>

Incorporation by Reference

This Report of Foreign Issuer on Form 6-K shall be incorporated by reference into the Registration Statement on Form S-8 filed with the Securities and Exchange Commission on April 24, 2002 and the Registration Statement on Form S-8 filed with the Securities and Exchange Commission on October 25, 2002.

Alcon, Inc. Bösch 69 P.O. Box 62 6331 Hünenberg, Switzerland

For immediate release

Alcon Expects 2002 Sales to Approach \$3.01 billion

Hünenberg, Switzerland - January 13, 2003 - Alcon, Inc. (NYSE:ACL) announced today it expects 2002 global sales to total approximately \$3.01 billion, which would be a 9.5% increase over 2001 global sales, or about 10.0% excluding the impact of foreign exchange fluctuations. As a result of this performance, the company expects earnings to exceed its prior guidance for the fourth quarter and full year, adjusted for previously reported one-time items.

Pursuant to Swiss law, Alcon's board of directors will convene in Switzerland on February 18 to approve the company's audited financial results, which will be released after the close of business on February 19. Alcon will hold a conference call at 8:00 AM Eastern Time on February 20 to discuss 2002 performance and its outlook for 2003.

Alcon, Inc. (NYSE: ACL) is the world's leading eye care company. Alcon, which has been dedicated to the ophthalmic industry for more than 50 years, develops, manufactures and markets pharmaceuticals, surgical equipment and devices, contact lens care solutions and other vision care products that treat diseases, disorders and other conditions of the eye.

Caution Concerning Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements principally relate to statements regarding the expectations of our management with respect to the future performance of various aspects of our business. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by our forward-looking statements. Words such as "may," "will," "should," "could," "would," "expect," "plan," "anticipate," "believe," "hope," "intend," "estimate," "project," "predict," "potential" and similar expressions are intended to identify forward-looking statements. These statements reflect the views of our management as of the date of this press release with respect to future events and are based on assumptions and subject to risks and uncertainties and are not intended to give any assurance as to future results. Given these uncertainties, you should not place undue reliance on these forwardlooking statements. Factors that might cause future results to differ include, but are not limited to, the following: the development of commercially viable products may take longer and cost more than expected; changes in reimbursement procedures by third-party payers; competition may lead to worse than expected financial condition and results of operations; currency exchange rate fluctuations may negatively affect our financial condition and results of operations; pending or future litigation may negatively impact our financial condition and results of operations; litigation settlements may adversely impact our financial condition; product recalls or withdrawals may negatively impact our financial condition or results of operations; government regulation or legislation may negatively impact our financial condition or results of operations; changes in tax laws or regulations in the jurisdictions in which we and our subsidiaries are subject to taxation may adversely impact our financial

performance; supply and manufacturing disruptions could negatively impact our financial condition or results of operations. You should read this press release with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements. Except to the extent required under the federal securities laws and the rules and regulations promulgated by the Securities and Exchange Commission, we undertake no obligation to publicly update or revise any of these forward-looking statements, whether to reflect new information or future events or circumstances or otherwise.

###

13JAN03

For information, contact:
Doug MacHatton (Investor Relations)
800-400-8599
News media and other inquiries: Mary Dulle (Public Relations)
817-551-8058
www.alconinc.com

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Alcon, Inc. (Registrant)

Date January 14, 2003 By /s/ Guido Koller

Name: Guido Koller

Title: Senior Vice-President

Date January 14, 2003 By /s/ Stefan Basler

Name: Stefan Basler Title: Attorney-in-Fact